1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Key Questions Answered
1.5. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Future Estimates
3.2.2. Currency Coverage and Foreign Exchange Rate
3.2.2.1. Major Currencies Affecting the Market
3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
3.2.3.4. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Trade Policies
3.2.4.1. Impact of Trade Barriers on the Market
3.2.4.2. Strategies for Mitigating The Risks Associated with Trade Barriers
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
5. INTRODUCTION
5.1. Chapter Overview
5.2. Viral and Non-Viral Gene Transfer Techniques
5.3. Viral Vectors Used in Genetically Modified Therapies
5.4. Types of Viral Vectors
5.4.1. Adeno-associated Viral Vectors
5.4.1.1. Overview
5.4.1.2. Design and Manufacturing
5.4.1.3. Advantages
5.4.1.4. Limitations
5.4.2. Adenoviral Vectors
5.4.2.1. Overview
5.4.2.2. Design and Manufacturing
5.4.2.3. Advantages
5.4.2.4. Limitations
5.4.3. Lentiviral Vectors
5.4.3.1. Overview
5.4.3.2. Design and Manufacturing
5.4.3.3. Advantages
5.4.3.4. Limitations
5.4.4. Retroviral Vectors
5.4.4.1. Overview
5.4.4.2. Design and Manufacturing
5.4.4.3. Advantages
5.4.4.4. Limitations
5.4.5. Other Viral Vectors
5.4.5.1. Alphavirus
5.4.5.2. Foamy Virus
5.4.5.3. Herpes Simplex Virus
5.4.5.4. Sendai Virus
5.4.5.5. Simian Virus
5.4.5.6. Vaccinia Virus
5.4.5.5. Chimeric Viral Vectors
5.5. Types of Non-Viral Vectors
5.5.1. Plasmid DNA
5.5.2. Liposomes, Lipoplexes and Polyplexes
5.5.3. Oligonucleotides
5.5.4. Other Non-Viral Vectors
5.6. Gene Delivery using Non-Viral Vectors
5.6.1. Biolistic Methods
5.6.2. Electroporation
5.6.3. Receptor Mediated Gene Delivery
5.6.4. Gene Activated Matrix (GAM)
5.7. Applications of Viral and Non-Viral Vectors
5.7.1. Cell and Gene Therapy
5.7.2. Vaccine
5.8. Current / Ongoing Trends in Vector Development / Manufacturing
5.8.1. Vector Engineering
5.8.2. Cargo Engineering
5.9. Vector Manufacturing
5.9.1. Types of Vector Manufacturers
5.9.2. Viral Vector Manufacturing Processes
5.9.2.1 Vector Production
5.9.2.2. Adherent and Suspension Cultures
5.9.2.3. Unit Process Versus Multiple Parallel Processes
5.9.2.4. Cell Culture Systems for Production of Viral Vectors
5.9.2.4.1. Small Scale / Laboratory Scale Cell Culture Systems
5.9.2.4.2. Large Scale Cell Culture Systems
5.9.2.4.2.1. Stirred Tank Reactor Systems
5.9.2.4.2.2. Fixed Bed Reactors / Packed Bed Reactors
5.9.2.4.2.3. Wave Bioreactor Systems
5.9.2.5. Serum-Containing versus Serum-Free Media
5.9.3. Bioprocessing of Viral Vectors
5.9.3.1. AAV Vector Production
5.9.3.2. Adenoviral Vector Production
5.9.3.3. Lentiviral Vector Production
5.9.3.4. ? -Retroviral Vector Production
5.9.4. Key Challenges Associated with Vector Manufacturing
5.10. Future Perspectives
6. VIRAL VECTOR AND GENE THERAPY MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Viral Vector and Gene Therapy Manufacturers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Type of Product Manufactured
6.2.5. Analysis by Location of Vector Manufacturing Facility
6.2.6. Analysis by Type of Manufacturer
6.2.7. Analysis by Scale of Operation
6.2.8. Analysis by Location of Headquarters and Scale of Operation
6.2.9. Analysis by Type of Viral Vector Manufactured
6.2.10. Analysis by Scale of Operation and Type of Viral Vector Manufactured
6.2.11. Analysis by Application Area
6.2.12. Information on Production Capacity
7. VECTOR AND GENE THERAPY MANUFACTURERS (NON-INDUSTRY PLAYERS): MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Vector and Gene Therapy Manufacturers: Overall Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Location of Headquarters (Region)
7.2.3. Analysis by Location of Headquarters (Country)
7.2.3. Analysis by Type of Manufacturer
7.2.4. Analysis by Scale of Operation
7.2.5. Analysis by Type of Vector Manufactured
7.2.6. Analysis by Scale of Operation and Type of Vector Manufactured
7.2.7. Analysis by Application Area
8. VECTOR AND GENE THERAPY MANUFACTURING TECHNOLOGIES: MARKET LANDSCAPE
8.1. Chapter Overview
8.2. Vector and Gene Therapy Manufacturing Technologies: Overall Market Landscape
8.2.1. Analysis by Type of Technology
8.2.2. Analysis by Purpose of Technology
8.2.3. Analysis by Scale of Operation
8.2.4. Analysis by Type of Vector
8.2.5. Analysis by Application Area
8.2.6. Most Active Players: Analysis by Number of Technologies
8.3. Concluding Remarks
9. COMPANY COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Methodology and Key Parameters
9.3. Vector and Gene Therapy In-House Manufacturers: Company Competitiveness Analysis
9.3.1. Players based in North America
9.3.2. Players based in Europe
9.3.3. Players based in Asia-Pacific and Rest of the World
9.4. Vector and Gene Therapy Contract Manufacturing Organizations: Company Competitiveness Analysis
9.4.1. Players based in North America
9.4.2. Players based in Europe
9.4.3. Players based in Asia-Pacific and Rest of the World
9.5. Vector and Gene Therapy In-house Manufacturers and Contract Manufacturing Organizations: Company Competitiveness Analysis
9.5.1. Players based in North America
9.5.2. Players based in Europe
9.5.3. Players based in Asia-Pacific and Rest of the World
10. VECTOR AND GENE THERAPY MANUFACTURERS IN NORTH AMERICA
10.1. Chapter Overview
10.2. Key Players
10.2.1. Advanced BioScience Laboratories
10.2.1.1. Company Overview
10.2.1.2. Vector Manufacturing Portfolio
10.2.1.3. Recent Developments and Future Outlook
10.2.2. Catalent Biologics
10.2.2.1. Company Overview
10.2.2.2. Financial Information
10.2.2.3. Vector Manufacturing Portfolio
10.2.2.4. Recent Developments and Future Outlook
10.2.3. Charles River Laboratories
10.2.3.1. Company Overview
10.2.3.2. Financial Information
10.2.3.3. Vector Manufacturing Portfolio
10.2.3.4. Recent Developments and Future Outlook
10.2.4. Thermo Fisher Scientific
10.2.4.1. Company Overview
10.2.4.2. Financial Information
10.2.4.3. Vector Manufacturing Portfolio
10.2.4.4. Recent Development and Future Outlook
10.2.5. VectorBuilder
10.2.5.1. Company Overview
10.2.5.2. Financial Information
10.2.5.3. Vector Manufacturing Portfolio
10.2.5.4. Recent Developments and Future Outlook
10.3. Other Key Players
10.3.1. AGC Biologics
10.3.1.1. Company Overview
10.3.1.2. Vector Manufacturing Portfolio
10.3.2. Aldevron
10.3.2.1. Company Overview
10.3.2.2. Vector Manufacturing Portfolio
10.3.3. Matica Biotechnology
10.3.3.1. Company Overview
10.3.3.2. Vector Manufacturing Portfolio
10.3.4. Resilience
10.3.4.1. Company Overview
10.3.4.2. Vector Manufacturing Portfolio
11. VECTOR AND GENE THERAPY MANUFACTURERS IN EUROPE
11.1. Chapter Overview
11.2. Key Players
11.2.1. Lonza
11.2.1.1. Company Overview
11.2.1.2. Financial Information
11.2.1.3. Vector Manufacturing Portfolio
11.2.1.4. Recent Developments and Future Outlook
11.2.2. Touchlight
11.2.2.1. Company Overview
11.2.2.2. Vector Manufacturing Portfolio
11.2.2.3. Recent Developments and Future Outlook
11.3. Other Key Players
11.3.1. BioNTech Innovative Manufacturing Service (a subsidiary of BioNTech)
11.3.1.1. Company Overview
11.3.1.1. Vector Manufacturing Portfolio
11.3.2. Biovian
11.3.2.1. Company Overview
11.3.2.2. Vector Manufacturing Portfolio
11.3.3. Celonic
11.3.3.1. Company Overview
11.3.3.2. Vector Manufacturing Portfolio
11.3.4. Centre for Process Innovation
11.3.4.1. Company Overview
11.3.4.2. Vector Manufacturing Portfolio
11.3.5. CEVEC Pharmaceuticals
11.3.5.1. Company Overview
11.3.5.2. Vector Manufacturing Portfolio
11.3.6. Novartis
11.3.6.1. Company Overview
11.3.6.2. Vector Manufacturing Portfolio
11.3.7. Oxford BioMedica
11.3.7.1. Company Overview
11.3.7.2. Vector Manufacturing Portfolio
11.3.8. Sanofi
11.3.8.1. Company Overview
11.3.8.2. Vector Manufacturing Portfolio
12. VECTOR AND GENE THERAPY MANUFACTURERS IN ASIA-PACIFIC
12.1. Chapter Overview
12.2. Key Players
12.2.1. CoJourney
12.2.1.1. Company Overview
12.2.1.2. Vector Manufacturing Portfolio
12.2.1.3. Recent Developments and Future Outlook
12.2.2. Esco Aster
12.2.2.1. Company Overview
12.2.2.2. Vector Manufacturing Portfolio
12.2.2.3. Recent Developments and Future Outlook
12.2.3. Wuxi AppTec
12.2.3.1. Company Overview
12.2.3.2. Financial Information
12.2.3.3. Vector Manufacturing Portfolio
12.2.3.4. Recent Developments and Future Outlook
12.3. Other Key Players
12.3.1. Altruist Biotechnology
12.3.1.1. Company Overview
12.3.1.2. Vector Manufacturing Portfolio
12.3.2. Jiangsu Puxin Biopharmaceutical
12.3.2.1. Company Overview
12.3.2.2. Vector Manufacturing Portfolio
12.3.3. Nikon CeLL innovation
12.3.3.1. Company Overview
12.3.3.2. Vector Manufacturing Portfolio
13. PORTER’S FIVE FORCES ANALYSIS
13.1 Chapter Overview
13.2. Methodology and Assumptions
13.3. Key Parameters
13.3.1. Threats of New Entrants
13.3.2. Bargaining Power of Suppliers
13.3.3. Bargaining Power of Buyers
13.3.4. Threats of Substitute Products
13.3.5. Rivalry Among Existing Competitors
13.4. Concluding Remarks
14. PARTNERSHIPS AND COLLABORATIONS
14.1. Chapter Overview
14.2. Partnership Models
14.3. Vector and Gene Therapy Manufacturing: Partnerships and Collaborations
14.3.1. Analysis by Year of Partnership
14.3.2. Analysis by Type of Partnership
14.3.3. Analysis by Scale of Operation
14.3.4. Analysis by Type of Vector Manufactured
14.3.5. Analysis by Therapeutic Area
14.3.6. Analysis by Application Area
14.3.7. Most Active Players: Analysis by Number of Partnerships
14.3.8. Analysis by Geography
14.3.8.1. Local and International Agreements
14.3.8.2. Intercontinental and Intracontinental Agreements
14.4. Other Collaborations
15. RECENT EXPANSIONS
15.1. Chapter Overview
15.2. Type of Expansions
15.3. Vector and Gene Therapy Manufacturing: Recent Expansions
15.3.1. Analysis by Year of Expansion
15.3.2. Analysis by Type of Expansion
15.3.3. Analysis by Year and Type of Expansion
15.3.4. Most Active Players: Analysis by Number of Expansions
15.3.5. Most Active Players: Analysis by Amount Invested
15.3.6. Analysis by Type of Manufacturing Facility
15.3.7. Analysis by Scale of Operation
15.3.8. Analysis by Type of Vector Manufactured
15.3.9. Analysis by Application Area
15.3.10. Analysis by Geography
15.3.10.1. Intercontinental and Intracontinental Expansions
15.3.10.2. Analysis by Location of Expansion
16. STRATEGIC PARTNER ANALYSIS
16.1. Chapter Overview
16.2. Methodology and Key Parameters
16.3. Strategic Partner Analysis: Viral Vector based Therapy Developers
16.3.1. Opportunity for AAV Vector based Therapy Developers
16.3.1.1. Most Likely Partners
16.3.1.2. Likely Partners
16.3.1.3. Less Likely Partners
16.3.1.4. Least Likely Partners
16.3.2. Opportunity for Adenoviral Vector based Therapy Developers
16.3.2.1. Most Likely Partners
16.3.2.2. Likely Partners
16.3.2.3. Less Likely Partners
16.3.2.4. Least Likely Partners
16.3.3. Opportunity for Lentiviral Vector based Therapy Developers
16.3.3.1. Most Likely Partners
16.3.3.2. Likely Partners
16.3.3.3. Less Likely Partners
16.3.3.4. Least Likely Partners
16.3.4. Opportunity for Retroviral Vector based Therapy Developers
16.3.4.1. Most Likely Partners
16.3.4.2. Likely Partners
16.3.4.3. Less Likely Partners
16.3.4.4. Least Likely Partners
16.3.5. Opportunity for Other Viral Vector based Therapy Developers
16.3.5.1. Most Likely Partners
16.3.5.2. Likely Partners
16.3.5.3. Less Likely Partners
16.3.5.4. Least Likely Partners
16.4. Strategic Partner Analysis: Viral Vector based Purification Product Developers
16.5. Methodology and Key Parameters
16.5.1. Opportunity for AAV Vector based Purification Product Developers
16.5.1.1. Most Likely Partners
16.5.1.2. Likely Partners
16.5.2. Opportunity for Adenoviral Vector based Purification Product Developers
16.5.2.1. Most Likely Partners
16.5.2.2. Likely Partners
16.5.3. Opportunity for Lentiviral Vector based Purification Product Developers
16.5.3.1. Most Likely Partners
16.5.3.2. Likely Partners
16.5.4. Opportunity for Retroviral Vector based Purification Product Developers
16.5.4.1. Most Likely Partners
16.5.4.2. Likely Partners
16.5.5. Opportunity for Other Viral Vector based Purification Product Developers
16.5.5.1. Most Likely Partners
16.5.5.2. Likely Partners
17. EMERGING VECTORS
17.1. Chapter Overview
17.1.1. Alphavirus based Vectors
17.1.2. Anc80 based Vectors
17.1.3. Bifidobacterium longum based Vectors
17.1.4. Cytomegalovirus based Vectors
17.1.5. Listeria monocytogenes based Vectors
17.1.6. Minicircle DNA based Vectors
17.1.7. Myxoma Virus based Vectors
17.1.8. Self-Complementary Vectors
17.1.9. Sendai Virus based Vectors
17.1.10. Sleeping Beauty Transposons
17.1.11. Vaccinia Virus and Modified Vaccinia Ankara based Vectors
17.1.12. Chimeric Viral Vectors
18. KEY INSIGHTS
18.1. Chapter Overview
18.2. Vector and Gene Therapy Manufacturers: Key Insights
18.2.1. Analysis by Type of Manufacturer, Type of Vector Manufactured and Scale of Operation
18.2.2. Analysis by Type of Vector Manufactured and Company Size
18.2.3. Analysis by Type of Organization and Geography
18.2.3.1. Contract Manufacturing Organizations
18.2.3.2. In-House Manufacturers
18.2.3.3. In-House and Contract Manufacturing Organizations
18.2.4. Analysis by Type of Vector Manufactured and Location of Headquarters
18.2.4.1. AAV Vector Manufacturers
18.2.4.2. Adenoviral Vector Manufacturers
18.2.4.3. Lentiviral Vector Manufacturers
18.2.4.4. Retroviral Vector Manufacturers
18.2.4.5. Plasmid DNA Manufacturers
19. COST PRICE ANALYSIS
19.1. Chapter Overview
19.2. Factors Contributing to High Price of Viral Vector and Plasmid DNA based Therapies
19.3. Viral Vector and Plasmid DNA based Therapies: Pricing Models
19.3.1. Pricing Models Based on Expert Opinions
19.3.2. Pricing Models Based on Manufacturing Cost
19.3.2.1. Pricing Models Based on Technology Used
19.3.2.2. Pricing Models Based on Scale of Operation
19.3.2.3. Pricing Models Based on Type of Client
19.3.3. Prices of Different Types of Vectors
19.4. Concluding Remarks
20. OUTSOURCING: GO / NO-GO FRAMEWORK
20.1. Chapter Overview
20.2. Outsourcing: Go / No-Go Framework
20.3. Vector Manufacturing Outsourcing: Go / No-Go Framework
20.3.1. Key Parameters and Assumptions
20.3.2. Methodology
20.3.3. Results and Interpretations
20.3.3.1. Outsourcing: Go / No-Go Framework for Small Companies
20.3.3.2. Outsourcing: Go / No-Go Framework for Mid-Sized Companies
20.3.3.3. Outsourcing: Go / No-Go Framework for Large Companies
21. CAPACITY ANALYSIS
21.1. Chapter Overview
21.2. Methodology and Key Assumptions
21.3. Viral Vector and Plasmid DNA Manufacturing: Global Installed Capacity
21.4. Viral Vector Manufacturing: Global Installed Capacity
21.4.1. Analysis by Company Size
21.4.2. Analysis by Scale of Operation
21.4.3. Analysis by Location of Headquarters (Region)
21.4.4. Analysis by Location of Manufacturing Facility
21.5. Plasmid DNA Manufacturing: Global Installed Capacity
21.5.1. Analysis by Company Size
21.5.2. Analysis by Scale of Operation
21.4.3. Analysis by Location of Headquarters (Region)
21.5.4. Analysis by Location of Manufacturing Facility
21.6. Concluding Remarks
22. DEMAND ANALYSIS
22.1. Chapter Overview
22.2. Assumptions and Methodology
22.3. Global Demand for Viral Vectors and Plasmid DNA, 2023-2035
22.4. Global Clinical Demand for Viral Vectors and Plasmid DNA, 2023-2035
22.4.1. Analysis by Type of Vector
22.4.2. Analysis by Type of Therapy
22.4.3. Analysis by Therapeutic Area
22.4.4. Analysis by Geography
22.5. Global Commercial Demand for Viral Vectors and Plasmid DNA, 2023-2035
22.5.1. Analysis by Type of Vector
22.5.2. Analysis by Type of Therapy
22.5.3. Analysis by Therapeutic Area
22.5.4. Analysis by Geography
22.6. Demand and Supply Analysis
23. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
23.1. Chapter Overview
23.2. Market Drivers
23.3. Market Restraints
23.4. Market Opportunities
23.5. Market Challenges
23.6. Conclusion
24. GLOBAL VECTOR MANUFACTURING MARKET
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Global Vector Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
24.3.1. Scenario Analysis
24.3.1.1. Conservative Scenario
24.3.1.2. Optimistic Scenario
24.4. Key Market Segmentations
25. VECTOR MANUFACTURING MARKET, BY SCALE OF OPERATION
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Vector Manufacturing Market: Distribution by Scale of Operation, 2018, 2023 and 2035
25.3.1. Preclinical Scale: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.3.2. Clinical Scale: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.3.4. Commercial Scale: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.4. Data Triangulation and Validation
26. VECTOR MANUFACTURING MARKET, BY TYPE OF VECTOR
26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Vector Manufacturing Market: Distribution by Type of Vector, 2018, 2023 and 2035
26.3.1. AAV Vectors: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.3.2. Adenoviral Vectors: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.3.3. Lentiviral Vectors: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.3.4. Retroviral Vectors: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.3.5. Other Vectors: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.4. Data Triangulation and Validation
27. VECTOR MANUFACTURING MARKET, BY APPLICATION AREA
27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. Vector Manufacturing Market: Distribution by Application Area, 2018, 2023 and 2035
27.3.1. Cell Therapy: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.3.2. Gene Therapy: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.3.3. Vaccines: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.4. Data Triangulation and Validation
28. VECTOR MANUFACTURING MARKET, BY THERAPEUTIC AREA
28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Vector Manufacturing Market: Distribution by Therapeutic Area, 2018, 2023 and 2035
28.3.1. Oncological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
28.3.2. Rare Diseases: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
28.3.3. Immunological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
28.3.4. Neurological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
28.3.5. Sensory Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
28.3.6. Metabolic Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
28.3.7. Blood Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
28.3.8. Musculoskeletal Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
28.3.9. Infectious Diseases: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
28.3.10. Ophthalmic Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
28.3.11. Autoimmune Disorders: Forecasted Estimates (2026-2035)
28.3.12. Other Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
28.4. Data Triangulation and Validation
29. VECTOR MANUFACTURING MARKET, BY TYPE OF MANUFACTURER
29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. Vector Manufacturing Market: Distribution by Type of Manufacturer, 2018, 2023 and 2035
29.3.1. In-house Manufacturers: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
29.3.2. Contract Manufacturing Organizations: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
29.4. Data Triangulation and Validation
30. VECTOR MANUFACTURING MARKET, BY GEOGRAPHY
30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Vector Manufacturing Market: Distribution by Geography, 2018, 2023 and 2035
30.3.1. North America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.2. Europe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.3. Asia-Pacific: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.4. Middle East and North Africa: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.5. Latin America and Rest of the World: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.4. Data Triangulation and Validation
31. SURVEY ANALYSIS
31.1. Chapter Overview
31.2. Analysis by Seniority Level of Respondents
31.3. Analysis by Type of Manufacturer
31.4. Analysis by Scale of Operation
31.5. Analysis by Type of Vector Manufactured
33. EXECUTIVE INSIGHTS
33.1. Chapter Overview
33.2. Batavia Biosciences
33.2.1. Company Snapshot
33.2.2. Interview Transcript: Menzo Havenga, Chief Executive Officer
33.3. Touchlight
33.3.1. Company Snapshot
33.3.2. Interview Transcript: Tommy Duncan, Chief Operating Officer
33.4. HALIX
33.4.1. Company Snapshot
33.4.2. Interview Transcript: Djamel Deken, Business Developer
33.5. CEVEC Pharmaceuticals
33.5.1. Company Snapshot
33.5.2. Interview Transcript: Nicole Faust, Chief Executive Officer and Chief Scientific Officer
33.6. Clean Cells
33.6.1. Company Snapshot
33.6.2. Interview Transcript: Olivier Boisteau, Co-Founder / President, Laurent Ciavatti, Former Business Development Manager and Xavier Leclerc, Head of Gene Therapy
33.7. Massachusetts General Hospital
33.7.1. Organization Snapshot
33.7.2. Interview Transcript: Bakhos A Tannous, Director
33.8. CJ PARTNERS
33.8.1. Company Snapshot
33.8.2. Interview Transcript: Colin Lee Novick, Former Managing Director
33.9. Polypus Transfection
33.9.1. Company Snapshot
33.9.2. Interview Transcript: Géraldine Guérin-Peyrou, Director of Marketing and Technical Support
33.10. University of Nantes
33.10.1. Organization Snapshot
33.10.2. Interview Transcript: Eduard Ayuso, Former Scientific Director
33.11. ACGT
33.11.1. Company Snapshot
33.11.2. Interview Transcript: Semyon Rubinchik, Scientific Director
33.12. Delphi Genetics
33.12.1. Company Snapshot
33.12.2. Interview Transcript: Cedric Szpirer, Former Executive and Scientific Director
33.13. Amsterdam BioTherapeutics Unit
33.13.1. Organization Snapshot
33.13.2. Interview Transcript: Joost van den Berg, Former Director
33.14. VIVEBiotech
33.14.1. Company Snapshot
33.14.2. Interview Transcript: Naiara Tejados, Head of Communications
33.15. GEG Tech
33.15.1. Company Snapshot
33.15.2. Interview Transcript: Nicolas Grandchamp, Chief Scientific Officer
33.16. Richter-Helm BioLogics
33.16.1. Company Snapshot
33.16.2. Interview Transcript: Astrid Brammer, Key Account Management
33.17. Plasmid Factory
33.17.1. Company Snapshot
33.17.2. Interview Transcript: Marco Schmeer, Head of Project Management and Tatjana Buchholz, Former Marketing Manager
33.18. Waisman Biomanufacturing
33.18.1. Company Snapshot
33.18.2. Interview Transcript: Brian M Dattilo, Director of Business Development
33.19. EFS-West Biotherapy
33.19.1. Company Snapshot
33.19.2. Interview Transcript: Beatrice Araud, ATMP Key Account Manager
33.21. Independent Consultant
33.21.1. Interview Transcript: Jeffery Hung
LIST OF FIGURES
Figure 3.1 Viral and Non-Viral Techniques for Gene Transfer
Figure 3.2 Vector Production: Types of Manufacturers
Figure 3.3 Viral Vectors: Manufacturing Process
Figure 4.1 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Figure 4.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Figure 4.3 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Continent-wise)
Figure 4.4 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Country-wise)
Figure 4.5 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Figure 4.6 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Continent-wise )
Figure 4.7 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Country-wise)
Figure 4.8 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer and Company Size
Figure 4.9 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation
Figure 4.10 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Vector Manufactured
Figure 4.11 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Figure 5.1 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Figure 5.2 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Figure 5.3 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Continents)
Figure 5.4 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Countries)
Figure 5.5 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Figure 5.6 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facilities (Continents)
Figure 5.7 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facilities (Countries)
Figure 5.8 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
Figure 5.9 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation
Figure 5.10 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Figure 6.1 Vector and Gene Therapy Manufacturers (Non-Industry Players): Cumulative Trend by Year of Establishment
Figure 6.2 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Vector Manufacturing Facilities (Continents)
Figure 6.3 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Vector Manufacturing Facilities (Countries)
Figure 6.4 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Manufacturer and Location of Vector Manufacturing Facilities
Figure 6.5 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Operation
Figure 6.6 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Vector Manufactured
Figure 6.7 Logo Landscape: Distribution by Scale of Operation and Type of Vector Manufactured
Figure 6.8 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Application Area
Figure 7.1 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Technology
Figure 7.2 Vector and Gene Therapy Manufacturing Technologies: Distribution by Purpose of Technology
Figure 7.3 Vector and Gene Therapy Manufacturing Technologies: Distribution by Scale of Operation
Figure 7.4 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Vector Manufactured
Figure 7.5 Vector and Gene Therapy Manufacturing Technologies: Distribution by Application Area
Figure 7.6 Most Active Players: Distribution by Number of Technology
Figure 8.1 Company Competitiveness Analysis: Distribution of Players based in North America (In-House Manufacturers)
Figure 8.2 Company Competitiveness Analysis: Distribution of Players based in Europe (In-House Manufacturers)
Figure 8.3 Company Competitiveness Analysis: Distribution of Players based in Asia-Pacific and Rest of the World (In-House Manufacturers)
Figure 8.4 Company Competitiveness Analysis: Distribution of Players based in North America (Contract Manufacturing Organizations)
Figure 8.5 Company Competitiveness Analysis: Distribution of Players based in Europe (Contract Manufacturing Organizations)
Figure 8.6 Company Competitiveness Analysis: Distribution of Players based in Asia-Pacific and Rest of the World (Contract Manufacturing Organizations)
Figure 8.7 Company Competitiveness Analysis: Distribution of Players based in North America (Both In-House and Contract Manufacturing Organizations)
Figure 8.8 Company Competitiveness Analysis: Distribution of Players based in Europe (Both In-House and Contract Manufacturing Organizations)
Figure 8.9 Company Competitiveness Analysis: Distribution of Players based in Asia-Pacific and Rest of the World (Both In-House and Contract Manufacturing Organizations)
Figure 9.1 Danaher: Annual Revenues, 2014 - Q1 2022 (USD Billion)
Figure 9.2 Merck KGaA: Annual Revenues, 2014 - Q1 2022 (EUR Billion)
Figure 9.3 H.A.V.E.: AAV Vector Manufacturing Technology
Figure 9.4 bluebird bio: Annual Revenues, 2014 - Q1 2022 (USD Million)
Figure 9.5 Astellas Pharma: Annual Revenues, 2014 - 2021 (JPY Billion)
Figure 9.6 Emergent BioSolutions: Annual Revenues, 2014 - 2021 (USD Million)
Figure 9.7 FUJIFILM Holdings: Annual Revenues, 2013 - H1 FY 2021 (JPY Billion)
Figure 9.8 FUJIFILM Holdings: Revenues by Business Divisions, FY 2020 (JPY Billion)
Figure 9.8 Spark Therapeutics: Annual Revenues, 2014 - 9M 2019 (USD Million)
Figure 10.1 Charles River Laboratories: Annual Revenues, 2017 - Q1 2022 (USD Billion)
Figure 10.2 Lonza: Annual Revenues, 2014 - 2021 (CHF Billion)
Figure 10.3 AGC Biologics: Annual Revenues, 2020 - 2022 (JPY Billion)
Figure 10.4 Novasep: Viral Vector Manufacturing Process
Figure 10.5 Oxford BioMedica: Annual Revenues, 2014 - 2021 (GBP Million)
Figure 10.6 Sanofi: Annual Revenues, 2014 - Q1 2022 (EUR Billion)
Figure 10.7 uniQure: Annual Revenues, 2014 - Q1 2022 (USD Million)
Figure 11.1 Wuxi AppTec: Annual Revenues, 2017 - H1 2022 (RMB Million)
Figure 12.1 Thermo Fisher Scientific: Annual Revenues, 2017-Q1 2022 (USD Billion)
Figure 12.2 BioNTech Innovative Manufacturing: Annual Revenues, 2017-Q1 2022 (EUR Billion)
Figure 13.1 Recent Partnerships: Cumulative Year-wise Trend, 2015 - 2022
Figure 13.2 Recent Partnerships: Distribution by Type of Partnership
Figure 13.3 Recent Partnerships: Distribution by Type and Year of Partnership, 2015 - 2022
Figure 13.4 Recent Partnerships: Distribution by Scale of Operation
Figure 13.5 Recent Partnerships: Distribution by Type of Vector(s)
Figure 13.6 Recent Partnerships: Distribution by Therapeutic Area
Figure 13.7 Most Active Players: Distribution by Number of Partnerships
Figure 13.8 Recent Partnerships: Geographical Analysis
Figure 13.9 Recent Partnerships: Intercontinental and Intracontinental Agreements
Figure 14.1 Recent Expansions: Cumulative Year-wise Trend, 2015 - 2022
Figure 14.2 Recent Expansions: Distribution by Type of Expansion, 2015 - 2022
Figure 14.3 Recent Expansions: Distribution by Type and Year of Expansion, 2015 - 2022
Figure 14.4 Recent Expansions: Distribution of Amount Invested by Key Players
Figure 14.5 Recent Expansions: Distribution by Scale of Operation
Figure 14.6 Recent Expansions: Distribution by Type of Vector(s)
Figure 14.7 Recent Expansions: Distribution by Application Area
Figure 14.8 Most Active Players: Distribution by Number of Expansions
Figure 14.9 Recent Expansions: Intercontinental and Intracontinental Expansions
Figure 14.10 Recent Expansions: Distribution by Location of Expansion Project
Figure 17.1 Vector and Gene Therapy Manufacturers: Competitive Landscape by Type of Manufacturer, Type of Vector Manufactured and Scale of Operation
Figure 17.2 Vector and Gene Therapy Manufacturers: Logo Landscape by Company Size and Type of Vector Manufactured
Figure 17.3 Vector and Gene Therapy Contract Manufacturers: Distribution by Prominent Geographical Hubs
Figure 17.4 Vector and Gene Therapy In-House Manufacturers: Distribution by Prominent Geographical Hubs
Figure 17.5 AAV Vector Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 17.6 Adenoviral Vector Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 17.7 Lentiviral Vector Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 17.8 Retroviral Vector Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 17.9 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 18.1 Viral Vector and Plasmid DNA Cost Price Analysis: Vector Production Process and Relative Costs Involved
Figure 19.1 Global Installed Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Type of Vector Manufactured (in Liters)
Figure 19.2 Global Installed Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (in Liters)
Figure 19.3 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Figure 19.4 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Figure 19.5 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size (in Liters)
Figure 19.6 Global Installed Viral Vector Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Figure 19.7 Global Installed Viral Vector Manufacturing Capacity: Distribution by Scale of operation (in Liters)
Figure 19.8 Global Installed Viral Vector Manufacturing Capacity: Distribution by Geographical Location of Viral Vector Manufacturing Facilities (in Liters)
Figure 19.9 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size (in Liters)
Figure 19.10 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Figure 19.11 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Scale of operation
Figure 19.12 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Location of Plasmid DNA Manufacturing Facilities (in Liters)
Figure 20.1 Global Clinical Demand for Viral Vector and Plasmid DNA, 2022-2035 (Thousand Patients)
Figure 20.2 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector Manufactured (Thousand Patients)
Figure 20.3 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Figure 20.4 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Figure 20.5 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location (Thousand Patients)
Figure 20.6 Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients)
Figure 20.7 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector Manufactured (Thousand Patients)
Figure 20.8 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Figure 20.9 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Figure 20.10 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location (Thousand Patients)
Figure 20.11 Global Viral Vector Manufacturing: Demand and Supply (Scenario 1), 2022-2035
Figure 20.12 Global Viral Vector Manufacturing: Demand and Supply (Scenario 2), 2022-2035
Figure 20.13 Global Viral Vector Manufacturing: Demand and Supply (Scenario 3), 2022-2035
Figure 21.1 Viral Vector and Plasmid DNA Manufacturing Market, 2022-2035 (USD Million)
Figure 21.2 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Type of Vector Manufactured, 2022-2035 (USD Million)
Figure 21.3 Viral Vector and Plasmid DNA Manufacturing Market: Market Attractiveness Analysis by Type of Vector Manufactured, 2022-2035
Figure 20.4 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Application Area, 2022-2035 (USD Million)
Figure 20.5 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Therapeutic Area, 2022, 2028 and 2035 (USD Million)
Figure 20.6 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Scale of Operation, 2022-2035 (USD Million)
Figure 20.7 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Type of Manufacturer, 2022-2035 (USD Million)
Figure 20.8 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 20.9 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Figure 20.10 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022, 2028 and 2035 (USD Million)
Figure 20.11 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022, 2028 and 2035 (USD Million)
Figure 20.12 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Type of Vector Manufactured, 2022, 2028 and 2035 (USD Million)
Figure 20.13 AAV Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Figure 20.14 AAV Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 20.15 AAV Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 20.16 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Figure 20.17 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 20.18 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 20.19 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Figure 20.20 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 21.21 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.22 Retroviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.23 Retroviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 21.24 Retroviral Vector Manufacturing Market for Commercial Product: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.25 Plasmid DNA Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.26 Plasmid DNA Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 21.27 Plasmid DNA Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.28 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.29 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Figure 21.30 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022, 2028 and 2035 (USD Million)
Figure 21.31 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Type of Vector Manufactured, 2022-2035 (USD Million)
Figure 21.32 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.33 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Figure 21.34 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.35 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.36 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Figure 21.37 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.38 Lentiviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.39 Lentiviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Figure 21.40 Lentiviral Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.41 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.42 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Figure 21.43 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.44 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.45 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Figure 21.46 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.47 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.48 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Therapeutic Area, 2022, 2025 and 2035 (USD Million)
Figure 21.49 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Animal Model Used, 2022-2035 (USD Million)
Figure 21.50 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022, 2025 and 2035 (USD Million)
Figure 21.51 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Type of Vector Manufactured, 2022-2035 (USD Million)
Figure 21.52 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.53 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Figure 21.54 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.55 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.56 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Figure 21.57 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.58 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.59 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Figure 21.60 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.61 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.62 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Figure 21.63 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.64 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.65 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Figure 21.66 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.67 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Type of Vector Manufactured, 2022-2035 (USD Million)
Figure 21.68 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Scale of Operation, 2022-2035 (USD Million)
Figure 21.69 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 21.70 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 22.1 Porter’s Five Forces
Figure 22.2 Porter’s Five Forces: Harvey Ball Analysis
Figure 23.1 Key Drivers and Challenges: AAV Vectors
Figure 23.2 Key Drivers and Challenges: Adenoviral Vectors
Figure 23.3 Key Drivers and Challenges: Lentiviral Vectors
Figure 23.4 Key Drivers and Challenges: Retroviral Vectors
Figure 23.5 Key Drivers and Challenges: Plasmid DNA
Figure 24.1 Survey Analysis: Distribution by Seniority Level of Respondents
Figure 24.2 Survey Analysis: Distribution by Scale of operation
Figure 24.3 Survey Analysis: Distribution by Type of Vector Manufactured
Figure 25.1 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing DNA Market: Current Market Landscape of Viral Vectors
Figure 25.2 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing DNA Market: Current Market Landscape of Plasmid DNA
Figure 25.3 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing DNA Market: Current Market Landscape of Non-Industry Players
Figure 25.4 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing DNA Market: Current Market Landscape of Vector and Gene Therapy manufacturing Technologies
Figure 25.5 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing DNA Market: Recent Expansions and Partnerships
Figure 25.6 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing DNA Market: Strategic Partner Analysis
Figure 25.7 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing DNA Market: Capacity Analysis
Figure 25.8 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing DNA Market: Demand Analysis
Figure 25.9 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing DNA Market: Market Forecast and Opportunity Analysis
LIST OF TABLES
Table 3.1 Key Features of Viral Vectors
Table 3.2 Key Features of Small-scale Cell Culture Systems
Table 4.1 Viral Vector and Gene Therapy Manufacturers: List of Industry Players
Table 4.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Location of Viral Vector Manufacturing Facilities, Scale of operation and Type of Manufacturer
Table 4.3 Heat Map: Information on Location of Headquarters and Scale of operation
Table 4.4 Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Type of Viral Vector Manufactured
Table 4.5 Heat Map: Information on Scale of operation and Type of Viral Vector Manufactured
Table 4.6. Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Application Area
Table 4.7. Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Production Capacity
Table 5.1 Plasmid DNA and Gene Therapy Manufacturers: List of Industry Players
Table 5.2 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Company Size and Location of Headquarters
Table 5.3 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Location of Plasmid DNA Manufacturing Facilities, Scale of operation and Type of Manufacturer
Table 5.4 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Application Area
Table 5.5 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Production Capacity
Table 6.1 Vector and Gene Therapy Manufacturers: List of Non-Industry Players
Table 6.2 Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Scale of operation
Table 6.3 Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Type of Vector Manufactured
Table 6.4 Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Application Area
Table 7.1 Vector and Gene Therapy Manufacturing Technologies: List of Technology Platforms
Table 9.1 Vector and Gene Therapy Production in North America: List of Profiled Companies
Table 9.2 Advanced BioScience Laboratories: Recent Developments and Future Outlook
Table 9.3 Aldevron Plasmid DNA: QC Assays
Table 9.4 Aldevron: Recent Developments and Future Outlook
Table 9.5 Audentes Therapeutics: Recent Developments and Future Outlook
Table 9.6 BioReliance / SAFC Commercial (Merck KGaA): Recent Developments and Future Outlook
Table 9.7 bluebird bio: Recent Developments and Future Outlook
Table 9.8 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 9.9 FUJIFILM Diosynth Biotechnologies: Recent Developments and Future Outlook
Table 9.10 MeiraGTx: Recent Developments and Future Outlook
Table 9.11 MassBiologics: Recent Developments and Future Outlook
Table 9.12 Spark Therapeutics: Recent Developments and Future Outlook
Table 9.13 Vigene Biosciences: Recent Developments and Future Outlook
Table 10.1 Vector and Gene Therapy Production in Europe: List of Players Profiled
Table 10.2 Biovian: Recent Developments and Future Outlook
Table 10.3 Centre for Process Innovation: Recent Developments and Future Outlook
Table 10.4 Cobra Biologics: Recent Developments and Future Outlook
Table 10.5 FinVector: Recent Developments and Future Outlook
Table 10.6 Kaneka Eurogentec: Recent Developments and Future Outlook
Table 10.7 Lonza: Recent Developments and Future Outlook
Table 10.8 MolMed: Recent Developments and Future Outlook
Table 10.9 Novasep: Manufacturing Experience
Table 10.10 Novasep: Recent Developments Future Outlook
Table 10.11 Orchard Therapeutics: Recent Developments Future Outlook
Table 10.12 Oxford BioMedica: Recent Developments and Future Outlook
Table 10.13 Richter-Helm: Recent Developments and Future Outlook
Table 10.14 Sanofi: Recent Developments and Future Outlook
Table 10.15 uniQure: Recent Developments and Future Outlook
Table 10.16 Vibalogics: Recent Developments and Future Outlook
Table 10.17 VIVEbiotech: Recent Developments and Future Outlook
Table 10.18 Cell and Gene Therapy Catapult: Recent Developments and Future Outlook
Table 11.1 Wuxi AppTec: Recent Developments and Future Outlook
Table 11.2 List of Other Key Players Based in Asia Pacific
Table 13.1 Vector and Gene Therapy Manufacturing: List of Recent Partnerships, 2015-2020 (till September)
Table 13.2 Vector and Gene Therapy Manufacturing: List of Other Partnerships, 2015-2020 (till September)
Table 13.1 Vector and Gene Therapy Manufacturing: List of Recent Expansions, 2015-2020 (till September)
Table 13.2 Vector and Gene Therapy Manufacturing: Information on Scale of operation, Type of Vector Manufactured and Application Area, 2015-2020 (till September)
Table 13.1 AAV Vector-based Therapy Developers: Most Likely Partners
Table 15.2 AAV Vector-based Therapy Developers: Likely Partners
Table 15.3 AAV Vector-based Therapy Developers: Less Likely Partners
Table 15.4 AAV Vector-based Therapy Developers: Least Likely Partners
Table 15.5 Adenoviral Vector-based Therapy Developers: Most Likely Partners
Table 15.6 Adenoviral Vector-based Therapy Developers: Likely Partners
Table 15.7 Adenoviral Vector-based Therapy Developers: Less Likely Partners
Table 15.8 Adenoviral Vector-based Therapy Developers: Least Likely Partners
Table 15.9 Lentiviral Vector-based Therapy Developers: Most Likely Partners
Table 15.10 Lentiviral Vector-based Therapy Developers: Likely Partners
Table 15.11 Lentiviral Vector-based Therapy Developers: Less Likely Partners
Table 15.12 Lentiviral Vector-based Therapy Developers: Least Likely Partners
Table 15.13 Retroviral Vector-based Therapy Developers: Most Likely Partners
Table 15.14 Retroviral Vector-based Therapy Developers: Likely Partners
Table 15.15 Retroviral Vector-based Therapy Developers: Less Likely Partners
Table 15.16 Retroviral Vector-based Therapy Developers: Least Likely Partners
Table 15.17 Other Viral Vector-based Therapy Developers: Most Likely Partners
Table 15.18 Other Viral Vector-based Therapy Developers: Likely Partners
Table 15.19 Other Viral Vector-based Therapy Developers: Less Likely Partners
Table 15.20 Other Viral Vector-based Therapy Developers: Least Likely Partners
Table 15.21 AAV Vector Purification Product Developers: Most Likely Partners
Table 15.22 AAV Vector Purification Product Developers: Likely Partners
Table 15.23 Adenoviral Vector Purification Product Developers: Most Likely Partners
Table 15.24 Adenoviral Vector Purification Product Developers: Likely Partners
Table 15.25 Lentiviral Vector Purification Product Developers: Most Likely Partners
Table 15.26 Lentiviral Vector Purification Product Developers: Likely Partners
Table 15.27 Retroviral Vector Purification Product Developers: Most Likely Partners
Table 15.28 Retroviral Vector Purification Product Developers: Likely Partners
Table 15.29 Other Viral Vector Purification Product Developers: Most Likely Partners
Table 15.30 Other Viral Vector Purification Product Developers: Likely Partners
Table 18.1 Viral Vector and Plasmid DNA Cost Price Analysis: Expert Opinions / Primary Research
Table 18.2 Viral Vector and Plasmid DNA: Prices of Vectors
Table 19.1 Global Installed Viral Vector Manufacturing Capacity: Sample Data Set
Table 19.2 Global Installed Plasmid DNA Manufacturing Capacity: Sample Data Set
Table 19.3 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size
Table 19.4 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size
Table 20.1. Global Viral Vectors Manufacturing Annual Demand, 2022-2035 (1020 vg)
Table 20.2 Global Viral Vectors Manufacturing Annual Supply (Scenario 1), 2022-2035 (1020 vg)
Table 20.3 Global Viral Vector Manufacturing: Annual Supply (Scenario 2), 2022-2035 (1020 vg)
Table 20.4 Global Viral Vector Manufacturing: Annual Supply (Scenario 3), 2022-2035 (1020 vg)
Table 21.1 Viral Vector and Plasmid DNA: Active Clinical Studies (Vector-Based Cell and Gene Therapies)
Table 21.2 Viral Vector and Plasmid DNA: Distribution by Patients Enrolled in the Active Clinical Studies (Vector-Based Cell and Gene Therapies)
Table 21.3 Viral Vector and Plasmid DNA: Number of Active Clinical Trials (Vector-Based Cell and Gene Therapies), 2022-2035
Table 21.4 Viral Vector and Plasmid DNA: Number of Patients Enrolled in Active Clinical Trials (Vector-Based Cell and Gene Therapies), 2022-2035
Table 21.5 Viral Vector and Plasmid DNA: Approved / Late-Stage Cell and Gene Therapies
Table 24.1 Survey Response: Overview of the Participating Companies / Organizations
Table 24.2 Survey Response: Seniority Level of Respondents
Table 24.3 Survey Response: Type of Vector
Table 24.4 Survey Response: Scale of operation
Table 24.5 Survey Response: Vector Stabilization Technology
Table 24.6 Survey Response: Type of Manufacturer (In-house Production versus Contract Services)
Table 26.1 Batavia Biosciences: Key Highlights
Table 26.2 CEVEC Pharmaceuticals: Key Highlights
Table 26.3 Vigene Biosciences: Key Highlights
Table 26.4 Delphi Genetics: Key Highlights
Table 26.5 Clean Cells: Key Highlights
Table 26.6 Novasep: Key Highlights
Table 26.7 Amsterdam BioTherapeutics Unit (AmBTU): Key Highlights
Table 26.8 MGH Viral Vector Development Facility, Massachusetts General Hospital: Key Highlights
Table 26.9 Translational Vector Core, University of Nantes: Key Highlights
Table 26.10 CJ PARTNERS: Key Highlights
Table 26.11 ACGT: Key Highlights
Table 26.12 Richter-Helm: Key Highlights
Table 26.13 Plasmid Factory: Key Highlights
Table 26.14 Waisman Biomanufacturing: Key Highlights
Table 26.15 EFS-West Biotherapy: Key Highlights
Table 26.16 GEG Tech: Key Highlights
Table 27.1 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Table 27.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Table 27.3 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Continent-wise)
Table 27.4 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Country-wise)
Table 27.5 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Table 27.6 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Continent-wise )
Table 27.7 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Country-wise)
Table 27.8 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer and Company Size
Table 27.9 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation
Table 27.10 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Vector Manufactured
Table 27.11 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Table 27.12 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Table 27.13 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Table 27.14 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Continents)
Table 27.15 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Countries)
Table 27.16 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Table 27.17 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facilities (Continents)
Table 27.18 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facilities (Countries)
Table 27.19 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
Table 27.20 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation
Table 27.21 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Table 27.22 Vector and Gene Therapy Manufacturers (Non-Industry Players): Cumulative Trend by Year of Establishment
Table 27.23 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Vector Manufacturing Facilities (Continents)
Table 27.24 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Vector Manufacturing Facilities (Countries)
Table 27.25 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Manufacturer and Location of Vector Manufacturing Facilities
Table 27.26 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Operation
Table 27.27 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Vector Manufactured
Table 27.28 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Application Area
Table 27.29 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Technology
Table 27.30 Vector and Gene Therapy Manufacturing Technologies: Distribution by Purpose of Technology
Table 27.31 Vector and Gene Therapy Manufacturing Technologies: Distribution by Scale of Operation
Table 27.32 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Vector Manufactured
Table 27.33 Vector and Gene Therapy Manufacturing Technologies: Distribution by Application Area
Table 27.34 Most Active Players: Distribution by Number of Technology
Table 27.35 Danaher: Annual Revenues, 2014 - Q1 2022 (USD Billion)
Table 27.36 Merck KGaA: Annual Revenues, 2014 - Q1 2022 (EUR Billion)
Table 27.37 bluebird bio: Annual Revenues, 2014 - Q1 2022 (USD Million)
Table 27.38 Astellas Pharma: Annual Revenues, 2014 - 2021 (JPY Billion)
Table 27.39 Emergent BioSolutions: Annual Revenues, 2014 - 2021 (USD Million)
Table 27.40 FUJIFILM Holdings: Annual Revenues, 2013 - H1 FY 2021 (JPY Billion)
Table 27.41 FUJIFILM Holdings: Revenues by Business Divisions, FY 2020 (JPY Billion)
Table 27.42 Spark Therapeutics: Annual Revenues, 2014 - 9M 2019 (USD Million)
Table 27.43 Charles River Laboratories: Annual Revenues, 2017 - Q1 2022 (USD Billion)
Table 27.44 Lonza: Annual Revenues, 2014 - 2021 (CHF Billion)
Table 27.45 AGC Biologics: Annual Revenues, 2020 - 2022 (JPY Billion)
Table 27.46 Oxford BioMedica: Annual Revenues, 2014 - 2021 (GBP Million)
Table 27.47 Sanofi: Annual Revenues, 2014 - Q1 2022 (EUR Billion)
Table 27.48 uniQure: Annual Revenues, 2014 - Q1 2022 (USD Million)
Table 27.49 Wuxi AppTec: Annual Revenues, 2017 - H1 2022 (RMB Million)
Table 27.50 Thermo Fisher Scientific: Annual Revenues, 2017-Q1 2022 (USD Billion)
Table 27.51 BioNTech Innovative Manufacturing: Annual Revenues, 2017-Q1 2022 (EUR Billion)
Table 27.52 Recent Partnerships: Cumulative Year-wise Trend, 2015 - 2022
Table 27.53 Recent Partnerships: Distribution by Type of Partnership
Table 27.54 Recent Partnerships: Distribution by Type and Year of Partnership, 2015 - 2022
Table 27.55 Recent Partnerships: Distribution by Scale of Operation
Table 27.56 Recent Partnerships: Distribution by Type of Vector(s)
Table 27.57 Recent Partnerships: Distribution by Therapeutic Area
Table 27.58 Most Active Players: Distribution by Number of Partnerships
Table 27.59 Recent Partnerships: Geographical Analysis
Table 27.60 Recent Partnerships: Intercontinental and Intracontinental Agreements
Table 27.61 Recent Expansions: Cumulative Year-wise Trend, 2015 - 2022
Table 27.62 Recent Expansions: Distribution by Type of Expansion, 2015 - 2022
Table 27.63 Recent Expansions: Distribution by Type and Year of Expansion, 2015 - 2022
Table 27.64 Recent Expansions: Distribution of Amount Invested by Key Players
Table 27.65 Recent Expansions: Distribution by Scale of Operation
Table 27.66 Recent Expansions: Distribution by Type of Vector(s)
Table 27.67 Recent Expansions: Distribution by Application Area
Table 27.68 Most Active Players: Distribution by Number of Expansions
Table 27.69 Recent Expansions: Intercontinental and Intracontinental Expansions
Table 27.70 Recent Expansions: Distribution by Location of Expansion Project
Table 27.71 Global Installed Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Type of Vector Manufactured (in Liters)
Table 27.72 Global Installed Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (in Liters)
Table 27.73 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Table 27.74 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Table 27.75 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size (in Liters)
Table 27.76 Global Installed Viral Vector Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Table 27.77 Global Installed Viral Vector Manufacturing Capacity: Distribution by Scale of Operation (in Liters)
Table 27.78 Global Installed Viral Vector Manufacturing Capacity: Distribution by Geographical Location of Viral Vector Manufacturing Facilities (in Liters)
Table 27.79 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size (in Liters)
Table 27.80 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Table 27.81 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Scale ofOperation
Table 27.82 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Location of Plasmid DNA Manufacturing Facilities (in Liters)
Table 27.83 Global Clinical Demand for Viral Vector and Plasmid DNA, 2022-2035 (Thousand Patients)
Table 27.84 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector Manufactured (Thousand Patients)
Table 27.85 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Table 27.86 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Table 27.87 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location (Thousand Patients)
Table 27.88 Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients)
Table 27.89 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector Manufactured (Thousand Patients)
Table 27.90 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Table 27.91 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Table 27.92 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location (Thousand Patients)
Table 27.93 Global Viral Vector Manufacturing: Demand and Supply (Scenario 1), 2022-2035
Table 27.94 Global Viral Vector Manufacturing: Demand and Supply (Scenario 2), 2022-2035
Table 27.95 Global Viral Vector Manufacturing: Demand and Supply (Scenario 3), 2022-2035
Table 27.96 Viral Vector and Plasmid DNA Manufacturing Market, 2022-2035 (USD Million)
Table 27.97 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Type of Vector Manufactured, 2022-2035 (USD Million)
Table 27.98 Viral Vector and Plasmid DNA Manufacturing Market: Market Attractiveness Analysis by Type of Vector Manufactured, 2022-2035
Table 27.99 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.100 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Therapeutic Area, 2022, 2028 and 2035 (USD Million)
Table 27.101 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Scale of Operation, 2022-2035 (USD Million)
Table 27.102 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Type of Manufacturer, 2022-2035 (USD Million)
Table 27.103 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.104 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.105 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022, 2028 and 2035 (USD Million)
Table 27.106 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022, 2028 and 2035 (USD Million)
Table 27.107 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Type of Vector Manufactured, 2022, 2028 and 2035 (USD Million)
Table 27.108 AAV Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.109 AAV Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 27.110 AAV Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.111 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.112 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 27.113 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.114 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.115 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 27.116 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.118 Retroviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.119 Retroviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 27.120 Retroviral Vector Manufacturing Market for Commercial Product: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.121 Plasmid DNA Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.122 Plasmid DNA Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 27.123 Plasmid DNA Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.124 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.125 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Table 27.126 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022, 2028 and 2035 (USD Million)
Table 27.127 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Type of Vector Manufactured, 2022-2035 (USD Million)
Table 27.128 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.129 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Table 27.130 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.131 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.132 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Table 27.133 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.134 Lentiviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.135 Lentiviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Table 27.136 Lentiviral Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.137 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.138 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Table 27.139 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.140 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.141 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Table 27.142 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.143 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.144 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Therapeutic Area, 2022, 2025 and 2035 (USD Million)
Table 27.145 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Table 27.146 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022, 2025 and 2035 (USD Million)
Table 27.147 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Type of Vector Manufactured, 2022-2035 (USD Million)
Table 27.148 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.149 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Table 27.150 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.151 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.152 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Table 27.153 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.154 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.155 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Table 27.156 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.157 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.158 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Table 27.159 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.160 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.161 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Table 27.162 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.163 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Type of Vector Manufactured, 2022-2035 (USD Million)
Table 27.164 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Scale of Operation, 2022-2035 (USD Million)
Table 27.165 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 27.166 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.167 Survey Analysis: Distribution by Seniority Level of Respondents
Table 27.168 Survey Analysis: Distribution by Scale of operation
Table 27.169 Survey Analysis: Distribution by Type of Vector Manufactured
